查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844198

感染疾病疫苗市場按疫苗類型、給藥途徑、最終用戶和分銷管道分類－2025-2032年全球預測

Infectious Vaccines Market by Vaccine Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，感染疾病疫苗市場規模將達到 669.8 億美元，複合年成長率為 9.74%。

主要市場統計數據
基準年 2024 318.3億美元
預計年份：2025年 348.8億美元
預測年份：2032年 669.8億美元
複合年成長率 (%) 9.74%

本文簡要介紹了科學進步和不斷發展的企業發展如何重塑感染疾病疫苗的研發管道和模式。

在科學創新、公共衛生優先事項的演變以及操作實踐的改變的推動下，感染疾病疫苗領域正經歷著變革時期。在過去十年間，mRNA和減毒活病毒疫苗載體等平台技術的進步已從實驗性方法發展成為臨床檢驗的工具，並在預防和治療應用方面引起了廣泛關注。同時，結合疫苗、去活化疫苗、減毒活疫苗、次單位疫苗和類毒素疫苗等現有疫苗也透過製劑改進、聯合策略和標靶抗原工程不斷發展。

新型製造技術、改進的低溫運輸管理和數位化供應鏈視覺化正在推動疫苗在不同醫療機構之間更可靠地分發。監管法規也不斷調整以適應新型平台，同時保持嚴格的安全性和有效性標準。公共衛生計畫也日益重視擴大疫苗覆蓋範圍和成人免疫策略。因此，從生物製藥開發商到公共免疫項目，相關人員在重新調整產品開發、夥伴關係和部署計劃，以兼顧技術前景和實際運作。

這項納入構成了報告的核心，重點闡述了平台多樣性、創新的管理途徑、診所、醫院、藥房和衛生中心等終端用戶的動態變化，以及影響技術採納和應用效果的分銷機制。它為後續的詳細分析奠定了基礎，明確了科學機會與商業性和公共衛生需求之間的交匯點。

探討推動疫苗研發和部署實務快速演變的技術、監管和物流變革的融合趨勢

除了科學突破之外，感染疾病疫苗領域正受到一系列相互交織的變革的影響，這些變革影響著監管預期、供應鏈網路和醫療服務模式。首先，平台多樣化正在加速。傳訊RNA技術和病毒載體正從概念驗證規模化生產階段，而自擴增RNA和純化脂質奈米顆粒製劑則正在拓展其適應症範圍。成熟的疫苗平台，如結合疫苗、去活化疫苗和類毒素疫苗，也不斷發展，透過抗原工程、佐劑最佳化和新型給藥方式，提高了疫苗的免疫抗原性和持久性。

第二，給藥途徑的重要性日益凸顯。雖然肌注在許多項目中仍佔據主導地位，但皮內、鼻腔、口服和皮下給藥途徑因其能夠提高患者接受度、簡化物流並賦予粘膜免疫力而重新受到關注。第三，終端用戶的細分正在影響分銷策略。診所、醫院、藥房和衛生中心各自存在不同的營運限制和機遇，這些限制和機會影響包裝、低溫運輸要求和數位記錄的整合。第四，分銷通路日趨專業化，政府採購、醫院藥局、線上藥局和零售商都需要各自獨特的商業性策略。

這些變化共同創造了一個動態的環境，在這個環境中，開發和分銷的靈活性，加上戰略夥伴關係和監管遠見，將決定哪些項目能夠獲得廣泛和持續的採用。

對 2025 年關稅如何重塑疫苗生產和分銷的供應鏈、籌資策略和採購動態進行實際評估。

2025年起對疫苗原料、組件及相關耗材徵收關稅，為生產商、經銷商和採購機構帶來了新的營運挑戰。關稅措施影響了整個價值鏈的單價結構，迫使生產商重新評估其全球籌資策略，盡可能優先考慮本地生產，並加快供應商資格認證流程以增強供應韌性。同時，採購機構和公共衛生採購人員也採取了相應措施，重新評估供應商多元化策略，並更加重視合約保障，以降低供應中斷的風險。

關稅也會影響通路的經濟效益。醫院藥局、零售藥局、網路藥局和政府採購機構在採購決策中必須進一步考慮成本和合規性，這可能會改變進口產品與國產產品的相對吸引力。對於臨床研發公司而言，關稅帶來的累積成本影響促使它們考慮建立區域性生產夥伴關係和技術轉移協議，以降低關稅波動帶來的風險。

從下游角度來看，減少對專用低溫運輸組件和一次性給藥裝置依賴的給藥途徑可能更具實際吸引力，因為它們可以降低因輔助用品關稅而導致成本增加的風險。整體而言，2025年的關稅情勢凸顯了供應鏈透明度、合約彈性以及與採購機構積極溝通的重要性，這些措施對於在保障淨利率和供應連續性的同時維持准入至關重要。

詳細的細分洞察揭示了疫苗平台選擇、給藥途徑、終端用戶環境和分銷管道如何相互作用，從而影響疫苗的普及率。

細分市場層面的動態反映了疫苗類型、接種途徑、最終用戶和分銷管道的顯著差異，了解這些差異對於策略優先排序至關重要。就疫苗類型而言，結合疫苗（包括Hib結合疫苗、腦膜炎雙球菌結合疫苗和肺炎鏈球菌結合疫苗）對於兒童和高風險成人免疫計畫仍然至關重要，因為長期免疫抗原性和人群保護是這些計畫的重點。去活化疫苗，例如甲型肝炎疫苗、流感疫苗、脊髓灰質炎和狂犬病疫苗，由於其安全性已得到充分驗證且監管法規已廣泛認可，因此仍被廣泛使用。活病毒疫苗，例如流感活疫苗、麻疹活疫苗、口服脊髓灰質炎疫苗、德國麻疹和水痘疫苗，能夠提供強大的免疫反應，是大規模疫苗宣傳活動的核心，但需要謹慎處理和低溫運輸管理。次單元疫苗，例如蛋白質次單元和類病毒顆粒構建體，具有良好的安全性和可生產性，而針對白喉、百日咳和破傷風的類毒素疫苗仍然是許多免疫接種計劃的主要組成部分。腺病毒、MVA 和 VSV 等病毒載體因其能夠誘導強效的細胞介導免疫，在預防和治療方面仍被廣泛應用。

在考慮給藥途徑時，可選擇的途徑包括皮內注射、肌肉注射、鼻內注射、口服和皮下注射，每種途徑的操作要求和患者體驗各不相同，這會影響診所、醫院、藥房和衛生中心的採納。與醫院相比，全科診所和專科診所的容量和儲存需求不同，私立和公立機構的採購和配製流程也不同。城鄉都市區的公共衛生中心也面臨不同的物流限制。分銷管道，包括分為地方和國家級的政府機構、提供院內和門診服務的醫院藥房、直接銷售和透過平台銷售的線上藥房，以及分為連鎖和獨立模式的零售藥房，進一步影響著商業性模式。這些細分維度相互影響。例如，成人肌肉注射的蛋白質次單元疫苗與透過國家公共衛生競標採購的兒童鼻內注射減毒活疫苗，其分銷和採購管道可能截然不同。

認知到這些相互依存關係，相關人員就可以調整其開發、製造和商業化策略，使其與目標細分市場的具體要求一致，從而加快產品推廣速度，提高營運適應性。

關鍵的區域性因素解釋了美洲、歐洲、中東和非洲以及亞太地區醫療基礎設施和法規環境的差異將如何影響疫苗策略。

區域動態對產品設計、監管策略、製造地和部署重點有顯著影響。在美洲，完善的免疫接種計劃和發達的公立及私立醫療保健基礎設施支撐著複雜的銷售管道，包括醫院藥房以及廣泛的零售和線上藥房網路。因此，開發人員通常會優先考慮監管協調和支付方參與策略，這些策略既要體現民營市場機制，也要體現大規模公共醫療保健採購流程。

歐洲、中東和非洲的法律規範、公共衛生優先事項和供應鏈能力各不相同。歐洲部分地區擁有完善的監管管道和製造群，能夠快速部署新型平台；而中東和非洲地區則可能優先考慮耐熱配方、簡化的給藥途徑以及有助於提升本地能力以應對獲取限制的夥伴關係模式。該地區都市區醫療中心需要靈活的低溫運輸解決方案和部署策略，以適應不斷變化的基礎設施條件。

亞太地區蘊藏著巨大的頻譜，從先進的製造地到快速發展的公共衛生體系，不一而足。擁有強大生物技術生態系統的國家正大力投資mRNA、病毒載體和下一代生產能力，而其他國家則專注於利用成熟的結合疫苗、去活化疫苗和類毒素疫苗擴大常規免疫覆蓋範圍。在全部區域策略是任何疫苗計劃的核心要素，因為區域優先事項會影響產品規格、監管時間表和供應鏈投資。

從策略層面整合公司和合作夥伴如何協調平台投資、製造能力和協作生態系統，以確保競爭優勢。

生物製藥、生物技術和受託製造領域的領導企業正透過平台投資、策略聯盟和產能擴張等方式重新定義其競爭地位。一些研發企業專注於平台可擴展性，致力於建構平台（例如mRNA、病毒載體和蛋白質次單元）的再利用能力，以適應多種適應症，從而最大限度地提高研發效率。受託製造企業正在擴展灌裝和模組化生產能力，以滿足對傳統和新型疫苗的需求，同時專注於低溫運輸創新和一次性使用技術。

大型製藥企業、區域製造商和技術專家之間的合作有助於技術轉移、在地化生產和監管聯絡。同時，脂質奈米顆粒、佐劑和分析服務的專業供應商作為策略夥伴的重要性日益凸顯，他們提供的關鍵投入會影響產品的性能和可生產性。能夠支持加速臨床試驗流程和跨多個司法管轄區申報準備工作的臨床和監管諮詢公司也是寶貴的合作夥伴。

最後，整合免疫登記、不利事件監測和流行病學數據的監測和真實世界證據提供者正成為企業展現價值、最佳化核准後計畫以及支持定向疫苗宣傳活動的戰略資產。總而言之，這些趨勢凸顯了在複雜且快速變化的環境中保持競爭力，需要採取協調一致的夥伴關係、能力規劃和技術投資。

透過平台靈活性、製造韌性和有針對性的商業性合作，提出切實可行的建議，以提高採用率並降低營運風險。

產業領導者應採取多維策略，平衡技術創新、營運韌性和市場化部署。優先考慮平台靈活性，使他們能夠將研發資源輪調用於不同適應症，並快速應對新出現的病原體威脅。同時，投資於製造韌性，例如本地化生產、多元化的供應商網路以及模組化填充包裝能力，可以降低因外部衝擊和關稅造成的成本波動風險。領導者還應評估能夠降低物流複雜性、提高患者接受度並支持本地無針給藥方案的給藥途徑創新。

在商業性，根據特定終端使用者和通路需求調整分銷策略能夠加速產品推廣。例如，儘早與醫院配藥委員會、零售藥局連鎖和公共衛生採購負責人接洽，可以明確儲存和包裝要求，從而體現在定價和合約條款中。積極與監管機構溝通，並投資開發統一的附加檔，可以加快產品在多個司法管轄區的核准流程。最後，建立數據夥伴關係關係，進行上市後監測和真實世界療效監測，能夠更好地展現產品價值，並支持產品的持續推廣。

平台的多功能性、供應鏈的穩健性、有針對性的商業性合作以及對證據產生的承諾相結合，使行業領導者能夠調整其產品組合，抓住臨床和公共衛生機遇，同時降低營運風險。

對用於評估疫苗項目平台性能、供應鏈風險和相關人員細分的研究資訊來源和分析方法進行透明概述

該研究結合了公開的科學文獻、監管指導文件、行業技術報告以及對研發、生產、監管事務和採購領域專家的結構化訪談。主要定性資訊是透過與疫苗研發負責人、製造外包組織、供應鏈專業人員和公共衛生採購負責人的討論收集的，以了解營運實踐和策略重點。次要研究包括同行評審期刊、監管通告和技術白皮書，重點關注平台技術、給藥途徑和分銷創新。

分析方法包括平台比較評估、供應鏈風險映射和相關人員細分，旨在識別疫苗類型、接種途徑、最終用戶需求和分銷管道之間的關鍵相互依存關係。此外，還進行了情境評估，以評估關稅等政策變化對營運的影響，並考慮本地化、供應商多元化和替代包裝策略等策略性應對措施。在條件允許的情況下，研究結果經過資訊來源交叉檢驗，以確保其可靠性。同時，也召開了專家檢驗會議，以完善關鍵見解和切實可行的建議。

這種方法提供了技術可能性、營運限制和商業性路徑的整體情況，使決策者能夠得出切實可行的策略和投資結論，而無需依賴專有的市場估算。

總結報告強調，需要製定綜合性的科學、製造和商業策略，才能將技術進步轉化為對公共衛生的實質影響。

感染疾病疫苗處於快速發展的科學、政策和物流的交匯點，其成功取決於技術能力與實際發行策略的整合。從結合疫苗和去活化疫苗到mRNA、病毒載體、次單元構建體和類毒素，多種平台為滿足未被滿足的需求提供了多種途徑。然而，這些科學機會必須與實際操作相平衡，包括低溫運輸限制、採購機制和監管環境。

諸如2025年關稅等政策措施的累積影響凸顯了供應鏈透明度和彈性採購方式的必要性。基礎設施和監管成熟度的區域差異進一步強調了製定地域性策略的重要性。最終，那些選擇符合終端用戶需求的平台、投資於具有韌性和可擴展性的製造能力，並積極與支付方和公共衛生相關人員互動的組織，將更有能力將科學進步轉化為廣泛且永續的公共衛生影響。

這個結論強調，研發、生產和商業部門之間的協調行動對於發揮下一代疫苗的潛力至關重要，同時也要確保公平可靠的取得途徑。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • mRNA疫苗技術的進步使得針對特定感染疾病的疫苗能夠快速研發。
  • 擴大耐熱疫苗配方規模，以支持在資源匱乏地區分發感染疾病疫苗
  • 將新一代佐劑整合到感染疾病疫苗中，以增強其免疫抗原性和持久性。
  • 多病原體聯合疫苗的出現簡化了全球免疫接種計劃
  • 加強公私合營，為感染疾病疫苗研發提供資金並加速研發進程。
  • 利用基因組監測數據指導疫苗株的即時選擇和更新策略
  • 引入數位化低溫運輸監控解決方案，以確保疫苗在整個分銷網路中的有效性
  • 不斷完善的法規結構旨在加速創新感染疫苗平台的審查和核准

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章 按疫苗類型感染疾病疫苗市場

  • 共軛物
    • Hib 結合物
    • 腦膜炎雙球菌結合物
    • 肺炎鏈球菌結合物
  • 惰性
    • 甲型肝炎
    • 流感
    • 脊髓灰質炎
    • 狂犬病
  • 減毒活活病毒疫苗
    • 流感病毒
    • 麻疹
    • 口服脊髓灰質炎
    • 德國麻疹
    • 水痘
  • mRNA
    • 脂質奈米顆粒mRNA
    • 自擴增mRNA
  • 次單元
    • 蛋白質次單元
    • 類病毒顆粒
  • 類毒素
    • 白喉
    • 百日咳
    • 破傷風
  • 病毒載體
    • 腺病毒
    • MVA
    • VSV

第9章 依給藥途徑分類的感染疾病疫苗市場

  • 皮內注射
  • 肌肉內注射
  • 鼻內
  • 口服
  • 皮下

第10章 按最終用戶分類的感染疾病疫苗市場

  • 診所
    • 一般醫療
    • 專業
  • 醫院
    • 私人的
    • 公共
  • 藥局
    • 線上
    • 零售
  • 公共衛生中心
    • 遍遠地區
    • 都市區的

第11章感染疾病疫苗市場（依分銷管道分類）

  • 政府機構
    • 當地的
    • 全國
  • 醫院藥房
    • 在醫院裡
    • 門診
  • 網路藥房
    • 直接地
    • 平台
  • 零售藥房
    • 鏈
    • 獨立

第12章 各地區感染疾病疫苗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章感染疾病疫苗市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國感染疾病疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Sanofi SA
    • Moderna, Inc.
    • AstraZeneca plc
    • Johnson & Johnson
    • BioNTech SE
    • CSL Limited
    • Sinovac BIoTech Ltd.
Product Code: MRR-ED54C46E8F6D

The Infectious Vaccines Market is projected to grow by USD 66.98 billion at a CAGR of 9.74% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 31.83 billion
Estimated Year [2025] USD 34.88 billion
Forecast Year [2032] USD 66.98 billion
CAGR (%) 9.74%

A concise introduction outlining how scientific advances and operational evolution are reshaping infectious vaccine development pathways and delivery models

The infectious vaccines landscape is undergoing a transformative phase driven by scientific innovation, evolving public health priorities, and shifting operational practices. Over the last decade, advances in platform technologies such as mRNA and viral vectors have matured from experimental modalities into clinically validated tools, prompting broader interest across preventive and therapeutic indications. Concurrently, established modalities including conjugate, inactivated, live attenuated, subunit, and toxoid vaccines continue to evolve through formulation improvements, combination strategies, and targeted antigen design.

Emerging manufacturing techniques, improved cold chain management, and digital supply chain visibility are enabling more reliable distribution across diverse healthcare settings. Regulatory pathways are adapting to accommodate novel platforms while maintaining rigorous safety and efficacy standards, and public health programs are increasingly prioritizing broader vaccine access and adult immunization strategies. As a result, stakeholders from biopharma developers to public immunization programs are recalibrating product development, partnership, and deployment plans to reflect both technological promise and operational realities.

This introduction frames the report's focus on platform diversity, route-of-administration innovation, end-user dynamics across clinics, hospitals, pharmacies, and public health centers, and the distribution mechanisms that will shape uptake and impact. It sets the scene for detailed analysis that follows, identifying where scientific opportunity intersects with commercial and public health imperatives.

An exploration of converging technological, regulatory, and distributional shifts that are driving rapid evolution in vaccine development and deployment practices

The landscape for infectious vaccines is being reshaped by a set of converging shifts that extend beyond scientific breakthroughs to influence regulatory expectations, supply networks, and care delivery models. First, platform diversification is accelerating: messenger RNA technologies and viral vectors have moved from proof-of-concept to scalable manufacturing, while self-amplifying RNA and refined lipid nanoparticle formulations are increasing the range of feasible indications. Established platforms such as conjugate, inactivated, and toxoid vaccines are not standing still; they are benefitting from antigen engineering, adjuvant optimization, and novel presentation formats that improve immunogenicity and durability.

Second, administration routes are expanding in importance. Intramuscular delivery remains dominant for many programs, yet intradermal, intranasal, oral, and subcutaneous options are attracting renewed attention because they can improve patient acceptance, simplify logistics, or confer mucosal immunity. Third, end-user segmentation is influencing distribution strategies: clinics, hospitals, pharmacies, and public health centers each present distinct operational constraints and opportunities, shaping packaging, cold chain requirements, and digital record integration. Fourth, distribution channels are fragmenting and specializing, with government procurement, hospital pharmacies, online pharmacies, and retail outlets each requiring tailored commercial approaches.

Together, these shifts create a dynamic environment where agility in development and distribution, coupled with strategic partnerships and regulatory foresight, will determine which programs achieve broad and sustained adoption.

A pragmatic assessment of how 2025 tariff measures are reshaping supply chains, sourcing strategies, and procurement dynamics across vaccine manufacturing and distribution

The introduction of tariffs affecting vaccine inputs, components, and related consumables in 2025 has introduced a new operational variable for manufacturers, distributors, and procurement agencies. Tariff policies influence unit cost structures across the value chain, driving manufacturers to re-evaluate global sourcing strategies, prioritize localized production where feasible, and accelerate supplier qualification processes to maintain resilience. In parallel, procurement organizations and public health purchasers have responded by reassessing supplier diversification and by placing greater emphasis on contractual safeguards to mitigate supply disruptions.

Tariffs also affect the economics of distribution channels. Hospital pharmacies, retail and online pharmacies, and government procurement entities must integrate additional cost and compliance considerations into purchasing decisions, which can alter relative attractiveness of imported versus domestically produced products. For clinical developers, the cumulative cost effects have incentivized consideration of regional manufacturing partnerships and technology transfer agreements to reduce exposure to tariff-related volatility.

From a downstream perspective, routes of administration that reduce reliance on specialized cold chain components or disposable delivery devices may gain pragmatic appeal because they can lower the exposure to tariff-driven cost increases for ancillary supplies. Overall, the tariff landscape in 2025 underscores the importance of supply chain transparency, contractual flexibility, and proactive engagement with procurement bodies to preserve access while protecting margins and continuity of supply.

In-depth segmentation insights revealing how vaccine platform choices, administration routes, end-user settings, and distribution channels interact to shape adoption outcomes

Segment-level dynamics reflect pronounced heterogeneity across vaccine types, administration routes, end users, and distribution channels, and understanding these distinctions is essential for strategic prioritization. Across vaccine types, conjugate approaches-spanning Hib conjugate, meningococcal conjugate, and pneumococcal conjugate formats-remain essential for pediatric and high-risk adult programs where long-term immunogenicity and herd protection are priorities. Inactivated platforms, including hepatitis A, influenza, polio, and rabies formulations, continue to be widely used due to established safety profiles and broad regulatory familiarity. Live attenuated vaccines such as influenza live formulations, measles, oral polio, rubella, and varicella offer potent immune responses and are central to mass immunization campaigns but require careful handling and cold chain management. mRNA technologies, differentiated into lipid nanoparticle mRNA and self-amplifying mRNA, are rapidly expanding into new indications because of their development speed and antigen design flexibility. Subunit approaches, including protein subunit and virus-like particle constructs, provide attractive safety and manufacturability attributes, while toxoid vaccines targeting diphtheria, pertussis, and tetanus remain pillars of many immunization schedules. Viral vectors such as adenovirus, MVA, and VSV continue to be leveraged for their ability to elicit strong cellular immunity in both prophylactic and therapeutic contexts.

When considering routes of administration, intradermal, intramuscular, intranasal, oral, and subcutaneous options create differing operational demands and patient experiences that influence adoption in clinics, hospitals, pharmacies, and public health centers. End-user settings vary widely: clinics encompassing general practice and specialty care have different throughput and storage needs compared with hospitals, where private and public institutions have distinct procurement and formulary processes; pharmacies operate across online and retail formats with unique customer interfaces; and public health centers in rural and urban settings confront divergent logistical constraints. Distribution channels-government agencies divided into local and national tiers, hospital pharmacies operating in-hospital and outpatient services, online pharmacies delivering direct and platform-mediated sales, and retail pharmacies split between chain and independent models-further shape commercial approaches. These segmentation dimensions interact; for example, a protein subunit vaccine delivered intramuscularly for adult use may follow a distinct distribution and procurement path than an intranasal live attenuated pediatric vaccine procured through national public health tenders.

Recognizing these interdependencies enables stakeholders to align development, manufacturing, and commercialization strategies with the specific requirements of target segments, reducing time to adoption and enhancing operational fit.

Key regional considerations explaining how distinct healthcare infrastructures and regulatory environments in the Americas, EMEA, and Asia-Pacific shape vaccine strategy

Regional dynamics exert a strong influence on product design, regulatory strategy, manufacturing footprint, and deployment priorities. In the Americas, established immunization programs and well-developed private and public healthcare infrastructures support advanced distribution channels such as hospital pharmacies and extensive retail and online pharmacy networks, while also providing fertile ground for next-generation platforms and adult immunization initiatives. Consequently, developers often prioritize regulatory alignment and payer engagement strategies that reflect both private market mechanisms and large-scale public health procurement processes.

Europe, Middle East & Africa present a mosaic of regulatory frameworks, public health priorities, and supply chain capabilities. In parts of Europe, sophisticated regulatory pathways and manufacturing clusters allow for rapid adoption of novel platforms, whereas regions across the Middle East and Africa may prioritize thermostable formulations, simplified administration routes, and partnership models that support local capacity building to address access constraints. Public health centers in rural and urban areas across this region demand flexible cold chain solutions and deployment strategies that can operate under variable infrastructure conditions.

Asia-Pacific encompasses a wide spectrum from advanced manufacturing hubs to rapidly developing public health systems. Countries with strong biotech ecosystems are investing heavily in mRNA, viral vector, and next-generation manufacturing capabilities, while others focus on broadening routine immunization with established conjugate, inactivated, and toxoid vaccines. Across the region, there is heightened interest in technologies and distribution models that reduce supply chain vulnerability, enable local production, and support rapid scale-up during outbreaks. Taken together, regional priorities influence product specifications, regulatory timelines, and supply chain investments, making geographic strategy a central component of any vaccine program.

A strategic synthesis of how companies and partners are aligning platform investments, manufacturing capabilities, and collaborative ecosystems to secure competitive advantage

Leading organizations across biopharma, biotech, and contract manufacturing are redefining competitive positioning through combinations of platform investment, strategic alliances, and capacity expansion. Some developers are focusing on platform extensibility, meaning they are building capabilities to repurpose mRNA, viral vector, or protein subunit platforms for multiple indications to maximize development efficiency. Contract development and manufacturing organizations are expanding fill-finish and modular production capabilities to meet demand for both traditional and novel vaccine formats, with attention to cold chain innovations and single-use technologies.

Collaborative ecosystems are increasingly central: alliances between large pharmaceutical companies, regional manufacturers, and technology specialists facilitate technology transfer, local production, and regulatory navigation. In parallel, specialized suppliers of lipid nanoparticles, adjuvants, and analytical services are gaining importance as strategic partners because they provide critical inputs that affect product performance and manufacturability. Clinical and regulatory consultancies that can support accelerated clinical pathways and dossier preparation across diverse jurisdictions are also valued partners.

Finally, surveillance and real-world evidence providers that integrate immunization registries, adverse event monitoring, and epidemiological data are becoming strategic assets for companies seeking to demonstrate value, optimize post-approval programs, and support targeted vaccination campaigns. Collectively, these trends underscore the need for a coordinated approach to partnerships, capacity planning, and technology investment to maintain competitiveness in a complex and fast-evolving landscape.

Actionable recommendations that combine platform flexibility, manufacturing resilience, and targeted commercial engagement to enhance adoption and mitigate operational risk

Industry leaders should adopt a multi-dimensional strategy that balances technological innovation, operational resilience, and market-tailored deployment. Prioritizing platform flexibility enables organizations to pivot development resources across indications and respond quickly to emerging pathogen threats. At the same time, investing in manufacturing resilience - including localized production, diversified supplier networks, and modular fill-finish capacity - reduces exposure to external shocks and tariff-driven cost variability. Leaders should also evaluate route-of-administration innovations that can lower logistics complexity, improve patient acceptance, or enable needle-free delivery programs in community settings.

Commercially, aligning distribution strategies with the needs of specific end users and channels will accelerate adoption. For instance, engaging early with hospital formulary committees, retail pharmacy chains, and public health purchasers can clarify storage and packaging requirements and inform pricing and contracting approaches. Regulatory foresight is equally important: proactive dialogue with authorities and investment in harmonized dossier development expedite approvals across multiple jurisdictions. Finally, establishing data partnerships for post-market surveillance and real-world effectiveness monitoring strengthens value demonstrations and supports sustained uptake.

By combining platform versatility, supply chain robustness, targeted commercial engagement, and evidence-generation commitments, industry leaders can position their portfolios to capture clinical and public health opportunities while mitigating operational risks.

A transparent summary of research sources and analytical approaches used to evaluate platform performance, supply chain risks, and stakeholder segmentation across vaccine programs

This research synthesizes public scientific literature, regulatory guidance documents, industry technical reports, and structured interviews with subject-matter experts across development, manufacturing, regulatory affairs, and procurement. Primary qualitative inputs were collected through discussions with leaders in vaccine development, contract manufacturing organizations, supply chain specialists, and public health procurement officers to capture operational realities and strategic priorities. Secondary research encompassed peer-reviewed journals, regulatory agency communications, and technical white papers focused on platform technologies, administration routes, and distribution innovations.

Analysis methodologies included comparative platform assessment, supply chain risk mapping, and stakeholder segmentation to identify critical interdependencies among vaccine types, routes of administration, end-user requirements, and distribution channels. Scenario-based evaluation was applied to assess the operational implications of policy changes such as tariff measures, and to explore strategic responses including localization, supplier diversification, and alternative packaging strategies. Wherever possible, findings were cross-validated across multiple sources to ensure robustness, and expert validation sessions were conducted to refine key insights and practical recommendations.

This approach provides a holistic view of technological potential, operational constraints, and commercial pathways without relying on proprietary market estimates, enabling decision-makers to draw practical conclusions for strategy and investment.

A conclusive synthesis emphasizing the need for integrated scientific, manufacturing, and commercial strategies to convert technology advances into reliable public health impact

Infectious vaccines occupy a rapidly evolving intersection of science, policy, and logistics, where success depends on integrating technological capabilities with pragmatic delivery strategies. Platform diversity-from conjugate and inactivated vaccines to mRNA, viral vectors, subunit constructs, and toxoids-offers multiple pathways to address unmet needs, while administration route innovations open possibilities for improved population-level protection and easier deployment. However, these scientific opportunities must be balanced against operational realities including cold chain constraints, procurement mechanisms, and the regulatory landscape.

The cumulative impact of policy actions, such as the tariff measures introduced in 2025, highlights the need for supply chain transparency and flexible sourcing approaches. Regional differences in infrastructure and regulatory maturity further underscore the importance of tailoring strategies to geographic context. Ultimately, organizations that align platform selection with end-user needs, invest in resilient and scalable manufacturing, and engage proactively with payers and public health stakeholders will be best positioned to translate scientific advances into widespread, sustainable public health impact.

This conclusion emphasizes the imperative for coordinated action across R&D, manufacturing, and commercial functions to realize the potential of next-generation vaccines while ensuring equitable and reliable access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in mRNA vaccine technology enabling rapid development of targeted infectious disease immunizations
  • 5.2. Expansion of thermostable vaccine formulations supporting distribution of infectious vaccines in resource limited regions
  • 5.3. Integration of next generation adjuvants to enhance immunogenicity and durability of infectious disease vaccines
  • 5.4. Emergence of combination vaccines addressing multiple pathogens to streamline immunization schedules globally
  • 5.5. Increasing collaboration between public and private sectors to fund and accelerate infectious vaccine pipelines
  • 5.6. Adoption of genomic surveillance data to inform real time vaccine strain selection and update strategies
  • 5.7. Implementation of digital cold chain monitoring solutions ensuring potency of vaccines across distribution networks
  • 5.8. Regulatory frameworks evolving to expedite review and approval of innovative infectious vaccine platforms

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infectious Vaccines Market, by Vaccine Type

  • 8.1. Conjugate
    • 8.1.1. Hib Conjugate
    • 8.1.2. Meningococcal Conjugate
    • 8.1.3. Pneumococcal Conjugate
  • 8.2. Inactivated
    • 8.2.1. Hepatitis A
    • 8.2.2. Influenza
    • 8.2.3. Polio
    • 8.2.4. Rabies
  • 8.3. Live Attenuated
    • 8.3.1. Influenza Laiv
    • 8.3.2. Measles
    • 8.3.3. Oral Polio
    • 8.3.4. Rubella
    • 8.3.5. Varicella
  • 8.4. MRNA
    • 8.4.1. Lipid Nanoparticle MRNA
    • 8.4.2. Self-Amplifying MRNA
  • 8.5. Subunit
    • 8.5.1. Protein Subunit
    • 8.5.2. Virus-Like Particle
  • 8.6. Toxoid
    • 8.6.1. Diphtheria
    • 8.6.2. Pertussis
    • 8.6.3. Tetanus
  • 8.7. Viral Vector
    • 8.7.1. Adenovirus
    • 8.7.2. MVA
    • 8.7.3. VSV

9. Infectious Vaccines Market, by Route Of Administration

  • 9.1. Intradermal
  • 9.2. Intramuscular
  • 9.3. Intranasal
  • 9.4. Oral
  • 9.5. Subcutaneous

10. Infectious Vaccines Market, by End User

  • 10.1. Clinics
    • 10.1.1. General Practice
    • 10.1.2. Specialty
  • 10.2. Hospitals
    • 10.2.1. Private
    • 10.2.2. Public
  • 10.3. Pharmacies
    • 10.3.1. Online
    • 10.3.2. Retail
  • 10.4. Public Health Centers
    • 10.4.1. Rural
    • 10.4.2. Urban

11. Infectious Vaccines Market, by Distribution Channel

  • 11.1. Government Agencies
    • 11.1.1. Local
    • 11.1.2. National
  • 11.2. Hospital Pharmacies
    • 11.2.1. In-Hospital
    • 11.2.2. Outpatient
  • 11.3. Online Pharmacies
    • 11.3.1. Direct
    • 11.3.2. Platform
  • 11.4. Retail Pharmacies
    • 11.4.1. Chain
    • 11.4.2. Independent

12. Infectious Vaccines Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Infectious Vaccines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Infectious Vaccines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Pfizer Inc.
    • 15.3.2. Merck & Co., Inc.
    • 15.3.3. GlaxoSmithKline plc
    • 15.3.4. Sanofi S.A.
    • 15.3.5. Moderna, Inc.
    • 15.3.6. AstraZeneca plc
    • 15.3.7. Johnson & Johnson
    • 15.3.8. BioNTech SE
    • 15.3.9. CSL Limited
    • 15.3.10. Sinovac Biotech Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INFECTIOUS VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 321. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 322. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 327. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 328. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 329. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NA